Medical Travel Guide for Stem Cell Treatment in Japan
Before you travel, you’ll want to know whether your diagnosis actually matches what’s available in Japan—not just a rough fit, but what the evidence really shows, which results you can realistically measure, what the total cost involves, and what you’ll need to set up ahead of time.
We handle the paperwork and planning. Diagnosis, eligibility, consent, and any medical decision stay with your licensed physician.
Four Details Decide Whether an Offer Is Relevant to You
PMDA’s approved regenerative medical product list is current through May 2026. Each product has a defined indication and method of use; approval is not a general permit to use the same cells for unrelated diseases.1
Your diagnosis, stage, prior treatment and current function must match the product, study or provision plan being discussed.
PMDA product approval and provision under Japan’s regenerative medicine safety framework are different routes. Legal provision does not by itself prove clinical benefit.2
Confirm the cell source, dose, route, number of administrations, whether surgery is required, and whether immune suppression is part of the protocol.
Ask for disease-specific outcomes from the same cell product or protocol, with a similar patient group and a meaningful follow-up period.
Start With the Diagnosis, Not the Cell Type
Start with your confirmed diagnosis and where you are now. From there, you can check whether Japan has an approved product, a registered study, or another documented route that fits your specific case.
Diagnosis, specialist summary, recent imaging, relevant laboratory or pathology results, medication history and previous treatment response.
For non-PMDA product routes, the official jRCT system can be used to check registered clinical studies and regenerative medicine plan information.3
Motor function, walking, pain, heart-failure events, neurological disability or another validated outcome should be defined before any benefit is discussed.
For a fuller pre-screening checklist, check the indications and contraindications guide. For the legal route, review Japan registration and compliance requirements.
Where Current Japanese Product Routes Are Specific
These examples show why a disease name and the exact product or procedure must be matched before travel.4
What to Check for Cartilage, Stroke and Other Diagnoses
Two Numbers That Show Why Trial Design Matters
Early studies point researchers in the right direction, but they don’t give you a reliable personal success rate. Sometimes randomized data shows the opposite—that a hoped-for benefit simply isn’t there.
Seven patients received bilateral transplantation and were followed for 24 months. No serious adverse events were reported. Among six patients included in the efficacy analysis, four improved on the motor score measured in the OFF state. The study was small, open-label and single-center, so it cannot establish a population-wide success rate.5
In a randomized phase 2/3 study in Japan, the day-90 excellent outcome rate was 11.5% with MultiStem and 9.8% with placebo; the difference was not statistically significant. The study reported similar safety and did not show the planned short-term efficacy benefit.6
Got a diagnosis but not sure which evidence actually fits?
Send us your diagnosis, the latest specialist note and your recent imaging report. We’ll pull together the questions you’d want answered before sitting down with a doctor.
What Usually Needs to Be Clear Before Eligibility Can Be Judged
the exact condition, current severity and the date or course of progression.
medicines, surgery, rehabilitation or other accepted care and how you responded.
active infection, unstable heart or lung disease, bleeding risk, cancer history, immune status and anesthesia or surgery risk when relevant.
imaging, laboratory results, pathology, neurological scores, cardiac testing or joint assessment as required by the protocol.
what improvement would be meaningful enough to justify the procedure, risk, cost and recovery burden.
Every product and protocol comes with its own eligibility rules. We can get your file organized for review, but the final call on whether you qualify belongs to the medical team treating you.
Use the Right Outcome for Your Disease
There’s no single “stem cell success rate” that applies across the board. The endpoint worth tracking depends entirely on the disease, the product, the procedure, and when you measure.
Relevant for serious diseases such as advanced heart failure. Ask whether the evidence measured death, hospitalization or major adverse events, not only a laboratory or imaging change.
Parkinson’s, stroke, traumatic brain injury and spinal cord conditions need validated motor or disability measures. Small early trials cannot provide a reliable personal survival-benefit claim.
Joint and cartilage procedures should be judged by pain, daily function, structural repair where relevant, return to activity and the rehabilitation course.
Confirm neurosurgical risks, infection and bleeding monitoring, immune-management needs when applicable, medication changes and the schedule for neurological follow-up.
Confirm anesthesia and surgical risk, rhythm and heart-failure monitoring, admission expectations, rehabilitation and fitness to fly after discharge.
Confirm tissue collection, arthroscopy if used, pain control, infection and thrombosis precautions, weight-bearing limits and rehabilitation milestones.
Confirm the exact product and route, infusion-reaction monitoring, protocol-specific immune or clotting risks, observation requirements and emergency contact plan.
For a practical risk checklist, review the Japan safety guide. Risk varies by cell product, procedure and patient condition.
Ask for the Full Cost, Not Only the Cell Price
A useful estimate separates the product or cell-processing fee from the medical procedure and from travel. Overseas self-pay charges can differ from Japanese domestic reimbursement prices.
For scale only: Japan’s Ministry of Health, Labour and Welfare listed the May 2026 reimbursement price for one 18-vial set of AMCHEPRY at ¥55,306,737. This is a domestic product reimbursement figure, not an overseas-patient quotation; surgery, admission, testing, travel and other care can be separate.7
A written estimate should state currency, tax, what is included, what can change after medical review, cancellation terms and who pays if extra admission or complication care is needed. See the detailed Japan cost guide.
Book Travel Around the Medical Schedule
Don’t lock in your return flight until the medical team confirms the testing schedule, how long they’ll keep you for observation, what they need for discharge, and when it’s safe to fly.
Physician-ready records, imaging files, medication list, written estimate, procedure sequence and any visa documentation.
Allow time for repeat tests, informed consent, procedure, observation and the first planned follow-up rather than scheduling tourism tightly around care.
Leave with an English or usable medical summary, medication instructions, warning signs, rehabilitation plan and a contact route for the treating team.
Japan’s Ministry of Foreign Affairs states that the Medical Stay visa period may be 90 days, 6 months or 1 year depending on the patient’s condition. Multiple-entry validity can be up to 3 years where necessary. Stays longer than 90 days have additional requirements, including a Certificate of Eligibility when hospitalization is planned.8
Want to Know What Needs to Be Prepared Before You Book?
We can turn scattered reports, imaging and questions into a clear review file and a checklist for cost, timing and follow-up.
Japan Case Review and Travel Coordination
Our service helps you move from a diagnosis and a folder of medical files to a physician-ready case, a documented evidence and regulatory checklist, a cost-confirmation list and a practical travel sequence. We do not diagnose, prescribe, choose a treatment for you or promise eligibility.
We sort the diagnosis, timeline, imaging, laboratory results, medicines, prior procedures and current symptoms into a usable case summary.
We identify what should be verified in PMDA, jRCT or the relevant regenerative medicine documentation and flag claims that do not match the stated indication.
We build the question list for a licensed physician: eligibility, expected outcome, risks, procedure, recovery, follow-up and what would make the plan unsuitable.
We organize the itemized estimate, document sequence, timing, language support, companion needs and the information needed after you return home.
For cell-processing questions, see the CPC Cell Processing Center guide, including what to ask about cell source, processing, quality testing and traceability.
What You ReceiveSend the Records That Change the Decision
Start with the documents that confirm diagnosis, show current status and explain what has already been tried. A complete translation of every old record is usually not needed for the first non-clinical review.
Questions That Should Be Answered Before You Decide
How do I know whether my condition is a match?
Match the exact diagnosis, stage, prior treatment and current function to the indication and patient-selection rules of the proposed product, study or provision plan. A licensed physician must make the final eligibility decision.
Can anyone give me a success rate or survival rate?
There is no valid single rate for stem cell care. Ask for the outcome used in your disease, the same product or protocol, the number of patients, follow-up time and whether the evidence came from a controlled study. Survival is useful for some serious diseases but is not the main efficacy measure for many neurological or joint conditions.
Does legal provision in Japan mean the treatment is proven?
No. Regulatory compliance, product approval and proof of clinical benefit are related but different questions. Check the exact legal route and then assess the disease-specific evidence separately.
Can I know the total cost before travel?
You should ask for an itemized estimate after your records have been reviewed. It should separate cells or product, procedure, testing, admission, medicines, rehabilitation and follow-up, and it should explain which charges can change.
How long should I stay in Japan?
The procedure determines the stay. A stereotactic brain operation, cardiac surgery, arthroscopy and an outpatient administration have very different testing, observation and fitness-to-fly requirements. Confirm the medical schedule before booking the return journey.
Make the Next Decision With the Right Records in Front of You
Send us your diagnosis, the latest specialist summary, recent imaging or lab results, your current medicines, and what you’ve tried before. We’ll put together the file, flag the evidence and regulatory questions, and map out the cost and travel details that need confirming before a doctor review.
To get started, you’ll need: your confirmed diagnosis, the latest specialist note, recent imaging or lab reports, your current medicine list, and a record of previous major procedures. This information helps with education and travel planning—it’s not a substitute for diagnosis, medical advice, informed consent, or emergency care. Outcomes with regenerative medicine vary by disease, product, procedure, your condition, and follow-up. Nobody can guarantee a cure, survival benefit, eligibility, or a specific result.